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In 1997, an initial set of reporting standards for studies
directed at the endovascular repair of the infrarenal aortic
aneurysm was introduced by the Ad Hoc Committee for
Standardized Reporting Practices in Vascular Surgery of
the Society for Vascular Surgery/International Society for
Cardiovascular Surgery.1 Since this initial report, the rapid
evolution of the field has led to new concepts and insights
into factors that define success and clinicopathologic fea-
tures that have a measurable impact on outcome. Thus, a
revised set of recommended standards is presented to ac-
commodate these and other developments in this emerging
discipline.
CLASSIFICATION CRITERIA FOR ARTERIAL
ANEURYSMS
Recommendations regarding the definition and classi-
fication of arterial aneurysm have been previously pub-
lished.2 As noted in this initial document, precise nomen-
clature is desirable, but a risk of overclassification exists that
may result in small patient subgroups that preclude mean-
ingful data analysis. Moreover, no classification of aneu-
rysms on the basis of a single factor has proved to be entirely
satisfactory. Therefore, classification of aneurysm is recom-
mended with respect to a combination of factors, includ-
ing: (1) site; (2) etiology; and (3) clinicopathologic mani-
festations. In any one specific report, selection of only one
of these factors as the basis for classification may be appro-
priate.
Anatomic classification. All reports should classify
aortic aneurysms on the basis of site and extent of disease
(Table I). Respective definitions and recommended classi-
fication schemes for nonaortic arterial aneurysms have been
described in detail elsewhere.2
Etiologic classification. It is recommended that re-
ports identify arterial aneurysm etiology. Specifically,
distinction should be made between degenerative (ar-
teriosclerotic), anastomotic, infectious, inflammatory
(noninfectious), traumatic, and congenital aneurysms. Al-
though dissection may be associated with any of a number
of underlying causes, such as Marfan’s syndrome or hyper-
tension, it represents a distinct pathologic entity that
should be noted accordingly in clinical reports.
Clinical classification. Aneurysms should be catego-
rized by clinical presentation as asymptomatic or symptom-
atic. Specific symptoms and their time course should be
documented, including those related to compression or
erosion into neighboring structures, thrombosis, or embo-
lization. Rupture should distinguish between a free rup-
ture, fistulization into an adjacent organ, and a contained
rupture. In this regard, central hemodynamic status should
be reported, including blood pressure and response to
initial resuscitation (stable, unstable, cardiac arrest).
OUTCOME CRITERIA AND DEFINITIONS
The motivation for aneurysm treatment is elimination
of the risk of rupture and death. Therefore, by definition,
the primary outcome criteria for endovascular aneurysm
repair include the prevention of: (1) aneurysm rupture; (2)
death from aneurysm rupture; and (3) aneurysm-related
death that may result from primary or secondary treatment.
Nonetheless, the mere presence of a device does not nec-
essarily prohibit aneurysm rupture and death. Thus, surro-
gate markers that suggest a continuing or increasing risk of
rupture, such as aneurysm enlargement or endoleak, al-
though designated as secondary outcome criteria, play a
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critical role in the overall assessment of the effectiveness of
endovascular treatment strategies. All told, significant value
exists in reporting an accepted and unifying measure of
clinical success that combines the most significant of pri-
mary and secondary outcome criteria, which reflect the
goals of this treatment method. The following section
provides recommendations for the definition and reporting
of clinical success and associated outcome criteria that
impact on the clinical effectiveness of endovascular repair.
Definition of success
Defining the success of endovascular aneurysm repair
remains dependent on a consideration of both clinical and
radiographic criteria within the context of a historic stan-
dard established by open surgical repair in which the aneu-
rysmal segment is treated with in situ prosthetic graft
replacement. In this regard, a similar result can only be
accomplished with an endograft, if complete exclusion of
the aneurysm from the circulatory system is achieved. Some
investigators, however, have suggested that the presence of
a persistent type II endoleak after endovascular repair may
not be an absolute predictor of late aneurysm expansion
and rupture.3 Moreover, it has also been argued that a
measured reduction in rupture risk may be possible even in
the presence of a type II endoleak. In the absence of
definitive data, the relative predictive value for this and
other outcome criteria with respect to the risk of aneurysm
rupture remains incompletely defined. Thus, future inves-
tigations may lead to further refinement of the recom-
mended definitions of success presented herein.
Definition of technical success. Technical success re-
lates to periprocedural events that occur from the initiation
of the procedure and extend through the first 24-hour
postoperative period. Primary technical success is defined on
an intent-to-treat basis and requires the successful intro-
duction and deployment of the device in the absence of
surgical conversion or mortality, type I or III endoleaks, or
graft limb obstruction. A technical success thus implies the
following qualifying details:
1. Successful access to the arterial system using a remote
site (ie, the femoral, external iliac, common iliac, or
brachiocephalic arteries with or without use of a tempo-
rary or permanent prosthetic conduit to access these
arteries);
2. successful deployment of the endoluminal graft with
secure proximal and distal fixation;
3. absence of either a type I or III endoleak;
4. patent endoluminal graft without significant twist,
kinks, or obstruction (30% luminal stenosis or a pres-
sure gradient 10 mm Hg) by intraoperative measure-
ments.
Primary technical success can include the use of addi-
tional modular components, stents, or angioplasty, and
adjunctive surgical procedures. However, if unplanned en-
dovascular or surgical procedures are necessitated, the
terms assisted primary or secondary technical success, respec-
tively, should be used.
Secondary endpoints should be reported, such as pro-
cedure time, blood loss, blood transfusion, fluoroscopy
time, contrast load, recovery time, range and average num-
ber of days in an intensive care unit, and hospital length of
stay. However, these parameters do not enter into the
consideration of technical success rates.
Definition of clinical success. Clinical success should
be reported on an intent-to-treat basis and requires success-
ful deployment of the endovascular device at the intended
location without death as a result of aneurysm-related
treatment, type I or III endoleak, graft infection or throm-
bosis, aneurysm expansion (diameter 5 mm, or volume
5%), aneurysm rupture, or conversion to open repair.
Moreover, the presence of graft dilatation of 20% or more
by diameter, graft migration, or a failure of device integrity
classifies a case as a clinical failure. Clinical success can be
claimed for those cases with a type II endoleak only in the
absence of aneurysm expansion. As long as the significance
of a type II endoleak and its implication as a marker for late
clinical failure remains an area of active investigation, it is
recommended that reports clearly indicate the proportion
of patients classified as clinical successes that harbor a type
II endoleak.
The presentation of clinically meaningful success rates
mandates that the data are statistically valid for the time
period in question. Specifically, the standard deviation of
life table or Kaplan-Meier estimates should not exceed 10%.
The following temporal characterization of clinical success
is offered with this consideration in mind. Initial or 30-day
clinical success encompasses 30-day data. Short-term clinical
success includes outcome measures reported within a 30-day
to 6-month time frame. Mid-term clinical success refers to
all outcome measures that are statistically significant up to 5
years after endograft implantation. Long-term clinical suc-
cess includes all outcome measures that are statistically
significant beyond 5 years.
Primary clinical success is clinical success without the
need for an additional or secondary surgical or endovascu-
lar procedure. Assisted primary clinical success is clinical
Table I. Classification of aortic and iliac aneurysms by
anatomic site
Aorta
Ascending thoracic
Arch
Descending thoracic
Thoracoabdominal (types I to IV)
Abdominal
Suprarenal
Splanchnic and renal arterial involvement
Only renal artery involvement
Juxatrenal or pararenal (no normal aorta between upper
extent of aneurysm and renal arteries)
Infrarenal
Iliac
Common
External
Internal
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success achieved with the use of an additional or secondary
endovascular procedure. Secondary clinical success is clinical
success obtained with the use of an additional or secondary
surgical procedure (eg, the performance of a femoral-
femoral bypass for treatment of a unilateral limb occlusion
of a bifurcated endograft). Conversely, clinical failure in-
cludes a failure to deploy the endovascular device at the
intended location, the presence of a type I or III endoleak,
graft thrombosis or infection, aneurysm expansion (diam-
eter 5 mm, or volume 5%), aneurysm rupture, conver-
sion to open repair, or death as a result of aneurysm rupture
or aneurysm-related treatment. Moreover, the presence of
graft dilatation of 20% or more by diameter, graft migra-
tion, or a failure of device integrity classifies a case as a
clinical failure. Aneurysm rupture should be reported as
either a procedure-related aneurysm rupture (ie, perforation
of the aneurysm during the course of the implantation
procedure) or as a late aneurysm rupture that follows device
deployment.
Longitudinal reporting of clinical outcome mea-
sures. The following parameters are recommended for
inclusion in any comprehensive report of endovascular
aneurysm repair: survival; rupture-free survival; prevalence
of aneurysm rupture, death from aneurysm rupture, and
aneurysm-related death; freedom from aneurysm expan-
sion; freedom from type I and III endoleaks; prevalence of
type II endoleak; prevalence of secondary endoleak; en-
dograft patency; and technical and clinical success rates.
Life tables or Kaplan-Meier curves should be calculated
for presentation of survival and rupture-free survival, main-
tenance of clinical success, risk of aneurysm-related death,
as well as for freedom from aneurysm expansion and type I
or III endoleaks. Endograft patency should be reported in
life table or Kaplan-Meier format as primary, assisted pri-
mary, or secondary depending on the use of additional
endovascular or surgical procedures.
Changes in renal function may occur as a result of
suprarenal fixation of an endograft. Therefore, for those
patients in whom an endograft extends above the renal
artery orifices, a separate analysis should consider reporting
parameters relevant to long-term renal function, including
renal artery patency, incidence of segmental renal infarcts,
estimated glomerular filtration rates, hypertension, and
dialysis-free survival.
Comparing the clinical success of endovascular and
open surgical repair. Investigations that compare open
surgical and endovascular repair should report primary
outcome criteria for both treatment groups, as previously
defined. However, the use of a related although distinct
definition of clinical success is necessary for patients treated
with open surgery. Primary technical success for open surgi-
cal repair should be reported on an intent-to-treat basis and
should require replacement or bypass of the aneurysmal
segment with a prosthetic graft in the absence of mortality
or graft thrombosis either during surgery or during the
initial 24-hour postoperative period. If an unplanned sur-
gical procedure is necessitated, such as a splenectomy or
reexploration for bleeding, the term secondary technical
success should be used.
The definition of clinical success for open surgical repair
includes the absence of death as the result of aneurysm-
related treatment, graft infection or thrombosis, failure of
device integrity, including graft dilatation 20% or more by
diameter, and paraanastomotic aneurysm formation.
Should open repair consist of aneurysm exclusion and
bypass grafting, aneurysm expansion (diameter5 mm, or
volume 5%) or rupture would classify a case as a clinical
failure. Definitions of initial (30-day), short-term, mid-
term, and long-term clinical success and of primary, assisted
primary, and secondary clinical success otherwise remain
unchanged, as do recommendations for longitudinal re-
porting of clinical data. Other significant outcome vari-
ables, such as device integrity, quality of life, and cost
effectiveness can be compared with guidelines outlined
below. Likewise, grading schemes for reporting complica-
tions and their severity, although primarily focused in this
report on endovascular treatment, can be adapted with
little modification for open repair. Finally, in comparison of
two or more patient populations treated with open surgery
and endovascular approaches, adjusting for case severity
mix, particularly with respect to comorbid medical condi-
tions, can be performed with schemes described else-
where.4
Aortic and iliac artery remodeling
Because aneurysm size is the predominant factor deter-
mining risk of aneurysm rupture,5 changes in aneurysm
dimension have been used as a surrogate marker for clinical
efficacy after endovascular repair. Other morphologic
changes, including progressive iliac angulation and aortic
neck enlargement, may occur in response to either aneu-
rysm exclusion or associated degenerative changes in adja-
cent segments, respectively. These late changes in aortoiliac
anatomy have not been used in the definition of clinical
success after endovascular aneurysm repair. Nonetheless,
they may have a significant impact on late device perfor-
mance and treatment durability. Thus, characterizing mor-
phologic responses to endovascular intervention is useful
both in defining clinical outcome and in serving to suggest
mechanisms and engineering remedies in the event of a
device failure.
Changes in dimension of the aortic aneurysm. In
endovascular repair, the aneurysm sac is left intact and, as a
consequence, this feature plays an important role in out-
come assessment. Principally, changes in the dimension of
the residual sac assist in defining the success or failure of
aneurysm exclusion. Specifically, clinical correlation sug-
gests that aneurysm growth after endovascular repair is an
indicator of incomplete aneurysm exclusion, continued risk
of aneurysm rupture, and a presumed treatment failure.6 In
addition, secondary changes in the configuration of the
aortoiliac segment, in response to a reduction in aneurysm
size, may jeopardize the integrity or function of the endo-
vascular graft.
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Because variations in size occur in three dimensions,
both sac volume and diameter are relevant parameters for
defining changes in aneurysm size. It is noteworthy, how-
ever, that relatively small diameter shifts of 1 to 2 mm, that
may otherwise be difficult to accurately measure with con-
ventional imaging techniques, may be correlated with a
significant change in aneurysm volume.7-9
Methodology for measuring changes in aneurysm di-
ameter, volume, and length. Aneurysm size should be
expressed as either maximum diameter or volume. Modal-
ity, method, and definitions should be clearly described,
and comparisons should only be made between identical
sources. Preferably, maximum aneurysm diameter should
be measured perpendicular to the flow line of the vessel
with three-dimensional reconstructed computed tomo-
graphic (CT) scan images. Because the aneurysm cross
section often appears elliptic on axial images, the minor axis
of the ellipse (smaller diameter) is generally a closer approx-
imation of true maximum aneurysm diameter.10 The in-
traobserver and interobserver variability of diameter mea-
surements obtained from CT scan images range between 2
and 5 mm or 5% and 15%.11,12 Therefore, a diameter change
of 5 mm or more is considered significant. Blinding of
observers and data sets are recommended to minimize bias.
Total aneurysm volume is defined as the volume within
the native aortic wall, which extends from the level of the
most caudal renal artery to a reproducible distal landmark,
such as the aortic or iliac bifurcation. Lumenal aneurysm
volume is defined as the volume circumscribed by the
endograft, while nonlumenal aneurysm volume is com-
prised of thrombus and, if present, endoleak. Endograft
dilatation may be associated with an increase in lumenal
volume, while reduction in aneurysm size is principally
related to a decrease in nonlumenal volume. The term
complete aneurysm resolution should be used if the nonlu-
menal aneurysm volume is less than 10% of the original
nonlumenal volume noted after endograft implantation.
The intraobserver and interobserver variability for volume
measurements have ranged between 3% and 5%. Therefore,
a volume change of 5% or more is considered significant.8
A reduction in aortic length has been noted in associa-
tion with a reduction in aneurysm size and may be associ-
ated with predisposition for endograft buckling, kinking,
and component dislocation.13 Aortic length is recom-
mended to be measured from the most caudal renal artery
to a reproducible distal endpoint, such as the aortic bifur-
cation, along the flow line axis, as depicted in three-dimen-
sional reconstructed spiral CT scan images.14,15 Of note, in
the absence of three-dimenstional reconstruction, aneu-
rysm length is underestimated as determined from axial CT
scan images.16-18 Moreover, limitations also exist for angiog-
raphy performed with a calibrated marker catheter.14,19
Changes in dimension of the aortic neck. Long-
term aneurysm exclusion and device stabilization is depen-
dent on the maintenance of an effective attachment, con-
nection, or seal between the endograft and the host aorta.
Therefore, dilatation of the aorta at the site or sites in-
tended for primary endograft fixation may lead to treat-
ment failure either with device migration or via the occur-
rence of a new endoleak with aneurysm expansion.20-23
Methodology for measuring changes in neck dimen-
sion. Both diameter and cross-sectional area of the aortic
neck at the sites intended for sealing or graft attachment are
reportable parameters, and measurement perpendicular to
the flow line is recommended. If the aortic segment does
not run perpendicular to the plane of measurement, the
smallest diameter (minor axis of the elliptical cross section)
is an appropriate approximate of the true neck diameter.20
Notably, the outer perimeter of the aortic neck wall should be
used as the reference point for all measurements. Modality,
method, and definitions should be clearly described, and
comparisons should only be made between identical sources.
Changes in dimension of the iliac arteries. Progres-
sive angulation of the aortoiliac segment leading to distor-
tions of the endograft can accompany reductions in aneu-
rysm size. This may result in endograft disruption or limb
occlusion. Likewise, progressive dilatation of an iliac artery
may also contribute to device instability or loss of effective
aneurysm exclusion. Accordingly, alterations in iliac artery
angulation and size after endovascular grafting and the
consequent responses of the prosthesis may be important
determinants of outcome.
Methodology for measuring changes in iliac artery
diameter and tortuosity. Three-dimensional image analy-
sis with appropriate anatomic referencing is recommended
for accurate determination of iliac angulation and tortuos-
ity. A second option is the presentation of measures derived
from oblique, anteroposterior, and lateral plain abdominal
x-rays that provide a simpler, albeit more approximate,
approach. Admittedly, if the latter approach is used, varia-
tions in position, angulation, and equipment may have a
significant impact on the reproducibility of derived mea-
sures. Definitions and categorization of iliac tortuosity and
angulation have been detailed elsewhere.4
Methodology for reporting sequential changes in
aortoiliac morphology. After placement of an endovas-
cular prosthesis, the local biomechanical and hemodynamic
environments of the native aorta are altered. As a conse-
quence, dynamic changes in aortoiliac morphology are
observed over time. The rate, magnitude, and direction of
this response will be influenced by properties inherent to
the chosen device and host aorta. Defining, with assured-
ness, the onset and durability of an unqualified treatment
success will require capturing the time course and the
direction of these associated morphologic changes.
Reporting morphologic changes that occur during a
study period. Changes in aneurysm dimension should be
reported in terms of prevalence (%) with the number of
available subjects at each time period clearly stated. In this
regard, the investigator should report the following out-
come measures: (1) reduction in abdominal aortic aneu-
rysm (AAA) diameter or volume by 5 mm or more or 5% or
more, respectively; (2) enlargement in AAA diameter or
volume by 5 mm or more or 5% or more, respectively; and
(3) absence of significant change either in AAA diameter or
volume. In characterizing the absence of aneurysm expan-
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sion at any time during a study period, life table or Kaplan-
Meier analysis is an appropriate form for data presentation,
as in freedom from aneurysm expansion.
Long-term studies are anticipated to provide data for
two additional outcome measures of increasing interest: (1)
complete aneurysm resolution; and (2) the rate of change
of aneurysm diameter or volume, with a distinction be-
tween population subgroups that show either an enlarge-
ment or reduction in aneurysm size. Measurable changes in
aneurysm dimensions have been reported immediately after
endograft deployment. Therefore, changes in aneurysm
size should be referenced to those measurements obtained
from the first set of postoperative images. Likewise, similar
methodologic approaches can be adopted for presenting
the changes of other morphologic features, such as aortic
neck diameter, aortic length, or iliac angulation.
Endoleak and endotension
Endoleaks, including their detection, potential clinical
significance, and treatment, remain an active area of inves-
tigation. However, although it is now evident that an
endoleak may resolve spontaneously, a proportion of those
that do persist have been associated with late aneurysm
rupture.24-27 Thus, endoleak remains an important mea-
sure of clinical outcome.
Definition of endoleak. Endoleak is defined by the
persistence of blood flow outside the lumen of the endolu-
minal graft but within the aneurysm sac, as determined by
an imaging study.28,29 An endoleak is evidence of incom-
plete exclusion of the aneurysm from the circulation and
may be the result of an incomplete seal between the en-
dograft and the wall of the blood vessel, an inadequate
connection between components of a modular prosthesis,
fabric defects or porosity, or retrograde blood flow from
patent aortic side branches.29,30 Although intrasac pressure
may approach systemic arterial pressure in the presence of
an endoleak, some type II endoleaks have been associated
with shrinking aneurysms and intrasac pressures that are
substantially less than systemic values.31
Classification of endoleak. An endoleak can be clas-
sified according to time of occurrence relative to the oper-
ative procedure and site of origin.32 An endoleak first
observed during the perioperative (30 days) period is
defined as a primary endoleak, and initial detection there-
after is termed a secondary endoleak.29 The reappearance of
an endoleak either after spontaneous resolution or after an
intervention that was considered successful is defined as a
recurrent endoleak. Further categorization requires precise
information regarding the course of blood flow into the
aneurysm sac (Table II). A Type I endoleak is indicative of a
persistent perigraft channel of blood flow caused by inade-
quate or ineffective seal at either the proximal or distal graft
ends or attachment zones. Use of subscripts a or b indicate
a type I endoleak originating at the proximal or distal ends
of the endograft, respectively. In the case of an aortoiliac
prosthesis, a type I endoleak may also refer to blood flow
around an iliac occluder plug and should be indicated with
use of subscript c. A type II endoleak is attributed to retro-
grade flow from lumbar arteries, the inferior mesenteric
artery (IMA), or other collateral vessels. Origin and outflow
sources of a type II endoleak should be specified, such as
lumbar-lumbar, lumbar-IMA, accesory renal-lumbar/
IMA, hypogastric-lumbar/IMA, or undefined. It should
be emphasized that any connection of flow to proximal or
distal graft ends or attachment zones, even in the presence
of retrograde flow from a lumbar or IMA vessel, classifies an
endoleak as type I. An endoleak caused by fabric tears or
disruption, component disconnection, or graft disintegra-
tion is classified as a type III endoleak. Distinction between
modular disconnection and fabric tear can be indicated
through the use of subscripts a and b, respectively. A type
IIIb endoleak can be further stratified with respect to the
extent of fabric disruption as major (2 mm) or minor (2
mm). An example of the latter is late “microleaks,” which
can develop at the site of suture attachment of a fabric to
supporting elements. Blood flow through an intact but
otherwise porous fabric, observed during the first 30 days
after graft implantation, is termed a type IV endoleak.32 This
designation is not applicable to fabric-related endoleaks
observed after the first 30-day period. If an endoleak is
visualized on imaging studies but the precise source cannot
be determined, the endoleak is categorized as an endoleak of
undefined origin.
Endotension. It is now appreciated that an AAA may
continue to enlarge after endovascular repair, even in the
absence of a detectable endoleak, and that this enlargement
may lead to aneurysm rupture.31,33-36 It has been proposed
that this condition be classified as endoleak-related.32 Ex-
planations for persistent or recurrent pressurization of an
aneurysm sac include blood flow that is below the sensitiv-
ity limits for detection with current imaging technolo-
gy32,34,37 or pressure transmission through thrombus38,39
or endograft fabric. On physical examination, the aneurysm
may be pulsatile and intrasac measurements may reveal
pressures that approach or are equal to systemic values.
At this time, endotension remains an investigative term
for which some disagreement persists regarding its precise
definition, appropriate usage, and current applicability. En-
dotension has been variably used in the literature to refer to
Table II. Classification of endoleak
Type Cause of perigraft flow
I a) Inadequate seal at proximal end of endograft
b) Inadequate seal at distal end of endograft
c) Inadequate seal at iliac occluder plug
II Flow from visceral vessel (lumbar, IMA, accessory
renal, hypogastric) without attachment site
connection
III a) Flow from module disconnection
b) Flow from fabric disruption
Minor ( 2 mm)
Major ( 2 mm)
IV Flow from porous fabric (30 days after graft
placement)
Endoleak of
undefined
origin
Flow visualized but source unidentified
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aneurysm enlargement in the presence or absence of an
endoleak and to persistent or recurrent pressurization of an
aneurysm sac, as determined with direct intrasac measure-
ment.36 It is anticipated that future research may lead to the
development of a surrogate marker for sac pressurization,
allowing more precise identification and definition of this
phenomenon. However, in the interim, the majority view
of this committee is that the term endotension be confined
to instances of aneurysm enlargement after endovascular
repair in the absence of a detectable endoleak. As such,
endotension should not be classified as an endoleak of
undefined origin.
Methodology for measuring the presence, source,
magnitude, and physiologic significance of endoleak
and endotension. Although conflicting studies exists,
most recent investigations suggest that the sensitivity of
contrast-enhanced CT scan imaging is superior to that of
other noninvasive techniques, such as duplex ultrasonogra-
phy, for endoleak detection.40 Nonetheless, CT scan imag-
ing may fail to identify an endoleak if delayed images are not
obtained after infusion of contrast medium.41 Further-
more, the sensitivity and specificity of available imaging
methods for endoleak detection have not been character-
ized. This may be particularly significant because of varying
degrees of metal-induced scattering artifact that may ob-
scure the identification of a small or subtle endoleak. Mo-
dality and method, including the use of angiography,
should be clearly stated, and comparisons should only be
performed with identical sources. Likewise, details should
be provided regarding techniques used for direct pressure
measurements of the aortic sac. Recently, specialized ultra-
sound scan techniques have been used to characterize the
elastic modulus or stiffness of the aortic wall as a potential
marker of intrasac pressure.42-44 Validation studies are not
yet complete, and conflicting results have been reported.45
Characterizing the frequency of endoleak in a study pop-
ulation during a defined observation period. The presence
or absence of an endoleak is an important component in the
definition of both early technical and late clinical success.
Therefore, the initiation of postimplant examinations for
endoleak identification should begin within 1 month after
graft implantation. Although recommendations exist with
respect to the timing of postoperative imaging studies, the
optimal frequency of follow-up examinations has not been
defined with prospective analysis. Current data do suggest,
however, that secondary or recurrent endoleaks appear at
an annual rate of approximately 10%, without evidence of a
significant decrease in prevalence over time. Therefore,
studies aimed at defining long-term success will continue to
require late imaging data.
Reports are recommended to include the prevalence
(%) of endoleak over the duration of the implant period. If
bar graphs are used to represent each time interval, the data
can be further stratified by: (1) time of endoleak occurrence
(primary, secondary, recurrent); or (2) site of endoleak
origin (types I to V), to provide additional perspective.
Similarly, endoleak data can be correlated with aneurysm
enlargement by plotting: (1) the proportion of patients
with a demonstrated endoleak; (2) the proportion of pa-
tients with a detectable endoleak and confirmed aneurysm
expansion; and (3) the proportion of patients without
detectable endoleak with demonstrable aneurysm expan-
sion (ie, possible endotension). The number of patients
available for analysis should be specified at each time point.
In characterizing the absence of endoleak at any time
during a study period, life table or Kaplan-Meier analysis is
an appropriate form for data presentation, as in freedom
from endoleak or endoleak-free survival. In this regard,
primary, assisted primary, and secondary curves, which are
distinguished on the basis of whether or not a secondary
surgical or catheter-based intervention was performed, can
be used to assess the role of endoleak-directed intervention.
Device integrity
Despite premarketing fatigue testing of endografts,
reports of structural failure throughout a wide range of
device types continue to be noted with some frequency,
including fractures of nitinol frames, elgiloy hooks, and
disruption of endograft fabric.46-51 To date, the total num-
ber of published reports that document a serious adverse
clinical event as the result of a structural failure remains
relatively small. However, as a new class of implantable
medical prosthesis, the impact of material fatigue and fail-
ure on long-term durability and clinical efficacy remains an
issue of significance. As endograft technology evolves, new
concepts or design modifications will require validation in a
clinical setting. A standard system for monitoring and
reporting device integrity will facilitate this process.
Methodology for documenting the integrity of an
endoprosthesis. The integrity of the endovascular device
may be compromised at the time of deployment (early
device failure) or at some late date after graft implantation
(late device failure). If disruption of a component of the
prosthesis is observed at the time of deployment, the role of
operator error, including inappropriate patient selection or
technical misjudgment, should be noted. Furthermore,
reports should distinguish between failure in the delivery
catheter, endograft, or related systems. A recommended
system for grading late deformation of endografts is pro-
posed. Grade 0 indicates no device deformation. Grade I is
used for devices with induced curvature, without acute
angulation. Grade II refers to the presence of an angulation
more than 30 degrees, and Grade III refers to angulation
more than 30 degrees in association with device obstruc-
tion (IIIa) or component module disconnection (IIIb).
The site of angulation should be specified.
Plain radiographs obtained in the anteroposterior, lat-
eral, and oblique positions can be used for noninvasive
assessment of the integrity of metallic graft components.
High-resolution spiral CT scan imaging provides an addi-
tional approach, although all imaging methods remain
limited in their ability to detect fabric failure. Investigations
aimed at characterizing long-term device durability should
contain late imaging data, which have been closely analyzed
for device integrity. The prevalence of a structural failure in
a carefully studied, unselected, and numerically significant
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subset of implanted devices can serve as a proper estimate of
device failure. However, it remains inappropriate to esti-
mate the prevalence of a given structural failure mode based
on the total number of implanted devices, unless all devices
have been properly imaged with the specific purpose of
detecting identifiable markers of the type of failure under
investigation.
The clinical significance of reported device failures
should be stratified as: 0, not associated with an adverse
clinical event or necessitating increased surveillance or in-
tervention; 1, necessitating increased surveillance but with-
out clinical event; 2, necessitating intervention to control
or manage; and 3, resulting in conversion, rupture, major
complication (see section on Complications) or death.
Reports of late device failure should also include potentially
relevant clinical, anatomic, and hemodynamic parameters,
such as implant duration, associated changes in aortoiliac
morphology, and blood pressure.
Quality of life and cost-effectiveness studies
At a time of finite societal resources, the benefit pro-
vided by new interventions must be weighed against their
expense. Therefore, studies designed to evaluate aortic
endograft technology should include an assessment of both
the cost of this technology and the quality of life of the
treated patient. Formal Markov decision analysis models
are recommended for application in studies designed to
evaluate the cost effectiveness of endografts. The value of
these models resides in their ability to incorporate interven-
tion-related immediate-term and long-term expenditures
and clinical outcome. In this regard, an effective analysis of
the costs/benefits of aortic endografts will require determi-
nation of the impact of this technology on a large number
of clinical outcome variables. Examples of variables that
would favor the use of endografts with respect to open
surgery include reduced hospital stay, diminished mortality
and morbidity, improved quality of life in the perioperative
period and over the long term, and reduced psychologic
stress. These benefits, however, may be offset by high initial
costs, expenditures related to monitoring and reinterven-
tion, and psychologic stress associated with the potential
for aneurysm recurrence.
The effect of either open surgery or endovascular repair
on a patient’s quality of life can be prospectively evaluated
with a variety of available instruments.52-54 For an eco-
nomic analysis, cost rather than charge data should be
gathered, analyzed, and include as many of the total costs as
possible, including preadmission imaging, postimplanta-
tion surveillance, and late secondary procedures. In re-
gional or national population-based economic studies, in-
vestigators should consider the additional costs of
endovascular intervention for patients who would not oth-
erwise be candidates for open surgery.
CATEGORIZATION OF OPERATIONS AND
PROCEDURES
Operations and procedures determine the magnitude,
complexity, and expense of endovascular aneurysm repair,
including all the additional procedures necessary to main-
tain a clinically durable result. Therefore, careful reporting
will assist in efforts designed to enhance treatment efficacy
either with revision of patient selection criteria, improve-
ment of critical intaoperative adjuncts, such as imaging,
anesthesia, and pharmacologic therapy, or refinement of
device design. In all cases, identification of procedural goals
and maneuvers and device components and configurations
is important.
Categorization and definitions of endografting
procedures, device configurations, and components
Precise description of the configuration, modularity,
fabric, support, and fixation structures of the endografting
system should be provided, if not detailed elsewhere, in
addition to an accounting of all adjunctive components,
devices, and maneuvers. Recommendations regarding uni-
form reporting of device configuration and components
follow.
Configuration. Endograft configuration can be cate-
gorized either as a straight tubular aortic or an iliac graft, as
an aortoiliac or an aortofemoral graft combined with con-
tralateral iliac occlusion and femorofemoral bypass, or as a
bifurcated or inverted Y-shaped graft. The prefix branched
or nonbranched can be used to indicate the presence of side
arms to visceral, brachiocephalic, or hypogastric vessels.
Modularity. Endografts should be categorized as
comprised of a single unibody graft or modular compo-
nents, which are assembled in situ within the vascular tree
of the patient. Modular grafts must have overlapping junc-
tions between components.
Endograft fabric. The nature of the graft material
should be identified. For example, this material may be
expanded polytetrafluoroethylene, knitted or woven poly-
ester fabric (Dacron), or some other material or combina-
tion thereof. Reports should provide details regarding
unique textile structures and whether the fabric is of stan-
dard thickness (ie, equivalent to that used in open repair). If
fabric thickness is less than that commonly used for pros-
theses in open repair, the thickness should be specified.
Support system. The nature of the support skeleton
of the device also should be defined. Reports should
state whether the system fully or partially supports the
graft, whether it is balloon expandable or self-expanding,
and whether the supporting framework is fixed to the graft
with stitches or otherwise incorporated within the graft.
Likewise, the geometric configuration and the material
composition also should be specified. For example, the
support skeleton may be a braided or nonbraided frame-
work and may be comprised of stainless steel, elgiloy,
nitinol, or some other metal or plastic struts.
Fixation components and techniques. Reports
should specify whether graft fixation is achieved with a
component that is an integral part of the support skeleton
or a separate or unique element of the endograft system.
The geometric configuration of these components should
be described, including whether hooks, pins, scales, barbs,
or other means are used and whether fixation is to be
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achieved with balloon or self-expansion or by a means
separate from endograft deployment. The material compo-
sition and the degree to which the fixation component ex-
tends above or below the graft material should be specified.
In addition to characterizing the actual fixation com-
ponents, the percent of graft oversizing relative to the host
artery diameter at the intended fixation sites should be
reported, because this may affect attachment and sealing.
Finally, the intended placement of a fixation system below
or above renal artery or other visceral or pelvic vessel orifices
should be noted.
Endograft extensions and intraluminal stents. The
nature of adjunctive devices to assure proper patency and
positioning of the endograft should be described. For
example, reports should include details of graft extensions
and the use of adjunctive intraluminal balloon expandable
or self-expanding stents.
Adjunctive maneuvers: preoperative, intraoperative,
and postoperative
Definitions. A principal procedure is one that the sur-
geon believes to contribute most to aneurysm treatment,
such as placement of endograft components. An adjunctive
procedure is any other procedure that is designed to aug-
ment the effects of the principal procedure, such as angio-
plasty of an iliac artery stenosis or placement of a bypass
graft between an external iliac and hypogastric artery. Such
procedures may occur in the preoperative, intraoperative,
or postoperative periods and should be designated in like
manner. An ancillary procedure is one that does not con-
tribute to the overall treatment of the aneurysm, such as the
simultaneous repair of an inguinal hernia. Primary proce-
dures refer to all interventions performed at the time of
initial endovascular repair. Secondary procedures include all
operations or endovascular interventions performed at a
later date.
Preoperative adjunctive maneuvers. Categorization
of preoperative adjunctive procedures is based on a consid-
eration of unique sets of common objectives that are most
often related to treatment of concomitant arterial occlusive
disease to facilitate access or a prophylactic intervention to
reduce the likelihood of endoleak or ischemia after en-
dograft deployment. For example, the treatment of con-
comitant arterial occlusive disease may be necessary to
improve access through the iliac arteries or to allow the
treatment of renal or visceral disease, which may be ren-
dered more difficult if performed after the principal proce-
dure. In addition, the management of collateral arteries
originating within the aneurysm may be necessary to pre-
vent type II collateral endoleak after endoluminal repair of
the aneurysm. The hypogastric arteries may require embo-
lization when an aneurysm involves the abdominal aorta
and the common iliac artery. The IMA and lumbar arteries
may require embolization in AAAs, and the celiac artery
may require embolization in thoracoabdominal aneurysms
in which the superior mesenteric and renal arteries do not
arise from the aneurysm. Finally, adjunctive procedures
may be necessary in anticipation of ischemia that may result
from the principal procedure, thereby necessitating pro-
phylactic treatment. With this in mind, a categorization
scheme for preoperative adjunctive maneuvers is provided
in Table III.
Intraoperative adjunctive maneuvers. It is recom-
mended that intraoperative adjunctive maneuvers be clas-
sified as planned procedures or unplanned procedures.
Planned procedures comprise techniques that are part of a
preformulated operative strategy, and unplanned proce-
dures are necessary for management of unintended compli-
cations or an otherwise unsatisfactory outcome. Categori-
zation schemes for planned and unplanned intraoperative
maneuvers are provided in Tables IV and V, respectively.
Postoperative adjunctive maneuvers. Postoperative
procedures should be categorized with respect to treatment
objectives, including local wound management, endoleak,
and graft limb occlusion. In addition to reporting proce-
dures used in the management of graft limb obstruction,
outcomes should be described in accordance with pub-
lished standards for reports dealing with lower extremity
Table IV. Intraoperative adjunctive maneuvers: Planned
procedures
Management of access site
Percutaneous arterial access closure
Modified access sites
Iliac artery/aorta
Direct
Via prosthetic tube graft sutured end-to-side to iliac
artery/aorta
Carotid artery
Repair of femoral aneurysm at access site by open
technology
Management of collateral arteries within aneurysm
Embolization of hypogastric arteries
Embolization of IMA
Management of arterial tortuosity
Brachiofemoral wire
Direct or indirect manual deformation of artery
“Pull-down” maneuver
Management of occlusive disease of iliac arteries
“Sizing” with arterial dilator
Balloon dilatation
Table III. Preoperative adjunctive maneuvers
Management of concomitant iliac/renal/visceral artery occlusive
disease
Balloon dilatation
Stent deployment
Management of collateral arteries originating within the aneurysm
Embolization of hypogastric arteries
Embolization of IMA
Embolization of lumbar arteries
Embolization of visceral arteries (celiac)
Management of arterial branches to be deliberately rendered
ischemic by the proposed principal procedure
Carotid/subclavian transposition or interposition graft for
aneurysm disease adjacent to subclavian artery
Splenorenal anastomosis
Hypogastric to external iliac artery bypass graft
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ischemia.55 A categorization scheme for planned intraop-
erative maneuvers is provided in Table VI.
Conversion to open surgical repair. Conversion
from endovascular to open repair may be required either at
the original operation (primary conversion) or on a subse-
quent occasion (secondary conversion). Secondary conver-
sion also should be classified as urgent or elective. For
example, secondary conversion for persistent endoleak in
an asymptomatic aneurysm is an elective procedure, and
conversion precipitated by aneurysm rupture or arterial
occlusion is an urgent intervention. Details of conversion
should be reported, including indication, site of aortic
control, and other relevant operative information. Addi-
tional imaging studies, such as angiography or intravascular
ultrasound, may be conducted in the operating room to
assist in a final determination of aneurysm suitability for
endovascular repair. Therefore, intent-to-treat should be con-
sidered initiated by any maneuver directed at treating the
aneurysm with an endovascular approach that follows the
completion of intraoperative preprocedural aneurysm imag-
ing.
REPORTING DEATHS AND COMPLICATIONS
Standardized reporting of deaths and complications is
necessary to establish endograft exclusion as safe and effec-
tive therapy for aortic aneurysm. These standards are nec-
essary to compare endovascular procedures with other min-
imally invasive techniques and conventional surgery for
patients at low and high risk. Thus, reports that carefully
compile these data will lead to the development of criteria
for selecting the most appropriate procedure for a given
patient and provide scientifically valid information for ad-
vances in the technology of endograft exclusion.
Deaths
All deaths that occur within 30 days of the operative
procedure should be categorized as operative deaths and
classified as either procedure-related or device-related.
Deaths that occur after 30 days should be considered late
deaths. The cause of late death and its relationship to the
implanted device or procedure should be noted. Aneurysm-
related deaths should be reported explicitly and are defined
as all deaths due to aneurysm rupture, a primary or second-
ary procedure, or surgical conversion. Because these issues
are frequently difficult to determine in the absence of an
autopsy or direct assessment at surgery, the reliability of the
information used to make these determinations should be
stratified. The cause of death should be classified as verified
if on the basis of autopsy findings, direct surgical observa-
tion that defines the status of the aneurysm, or definitive
imaging studies of the endograft obtained during the pa-
tient’s terminal illness. When this level of information is
unavailable, the cause and its relationship to the procedure
and device should be classified as probable if the clinical
picture is consistent and documented with reliable obser-
vations during the terminal illness. When these criteria
cannot be met, the cause of death should be considered
indeterminate.
Complications
Complications should be reported with standardized
definitions and severity scoring to make appropriate com-
parisons with other methods of therapy and to objectively
discern improvements or failures accruing from advance-
ments in device design. Difficulties may arise in determin-
Table VI. Postoperative adjunctive maneuvers
Management of wound complications at access site
Evacuation of hematoma
Operation for lymph fistula/lymphocele
Repair of false aneurysm
Management of ischemia of lower limbs
Balloon catheter thrombectomy/embolectomy at sites remote
from access site
Thrombectomy/endarterectomy at access site
Bypass graft
Femorofemoral
Femorodistal
Thrombolysis
Procedures that may be required for endoleak management
Endovascular procedures
Balloon dilatation at anchor zones
Open mesh stent deployment at anchor zones
Secondary endoluminal repair with aortic cuffs, extensions
involving deployment of secondary endoluminal
prosthesis within primary prosthesis
Coil embolization of patent collateral channels
Laparoscopic procedures
Clip ligation of IMA
Banding of anchor zones
Open procedures
Hand sewn anastomosis of endolimb to native iliac artery
Banding of anchor zones
Open conversion
Table V. Intraoperative adjunctive maneuvers:
Unplanned procedures
Management of perforation of iliac arteries/aorta
Endovascular repair
Bypass graft
Conversion to open repair
Management of obstructed blood flow to lower extremity with
thrombolysis, thrombectomy, endarterectomy, and patch
graft or bypass graft†
Management of endoleak identified on table†
Balloon dilatation at anchor zones
Open mesh stent deployment at anchor zones
Proximal aortic cuff deployment
Distal limb extension deployment
“Deflector” graft to convert bifurcated to aortouniiliac graft
Instillation of thrombin, gelatin sponge, coils, or other
thrombotic agents into aneurysm sac
Maneuvers designed to move an endovascular graft inferiorly
Traction on balloon catheter inflated within endograft
Traction on femorofemoral guidewire across prosthetic
bifurcation
Traction on graft with bronchoscopy forceps within sheath
Conversion from endoluminal to open repair
†Placement of additional stents, extender cuffs, or instillation of thrombotic
agents at time of primary endovascular aneurysm repair is not absolutely
indicative of “unplanned” procedure.
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Table VII. Classification and grading of complications
Complication Grading
Deployment-related complications
Failed deployment with or without conversion 1 No complications from attempted endovascular procedure, hospital stay not
prolonged after endovascular repair
2 Conversion to open repair, no permanent disability
3 Significant permanent disability that impairs employment, function, or ability
to live independently or death
Operative bleeding 1 Autotransfusion  2 units, no homologous transfusion
2 2 units autologous,  3 units homologous, limited incision for control
3  3 units homologous, laparotomy, thoracotomy, or necessitated exposure in
addition to initial vessel cutdown to control bleeding
Aortic dissection (within 30 days of AAA repair) 1 Incidentally noted, asymptomatic
2 Resolved with endovascular repair
3 Open repair or fatal
Arterial perforation or rupture 1 Spontaneous closure
2 Stent graft or limited retroperitoneal iliac repair at primary procedure
3 Laparotomy/thoracotomy
Access artery dissection or thrombosis 1 Incidentally noted, non–flow limiting dissection, local repair/prophylactic
patch closure of access artery
2 Stent, limited retroperitoneal bypass, or necessitated return to operating room
for thrombosis
3 Conversion to open AAA repair
Peripheral microembolization 1 Resolution without tissue loss
2 Minor tissue loss, including toe or ray amputation
3 Major amputation or significant tissue loss
Peripheral macroembolization 1 Resolution with intraoperative embolectomy at primary procedure
2 Embolectomy or other minor secondary operation, minor tissue loss
3 Arterial bypass or major arterial repair, major amputation
Access site hematoma 1 Spontaneous resolution
2 Surgical evacuation
3 Nerve compression or associated arterial repair
Access site false aneurysm 1 Resolved spontaneously, with compression, or thrombin therapy
2 Surgical repair
3 Ruptured
Access site lymphocele, lymphorrhea,
lymphedema
1 Resolution with or without aspiration, minor edema easily controlled with
elastic support
2 Open drainage or repair
3 Permanent debilitating edema
Access site infection 1 Resolved with oral antibiotics
2 Operative drainage, intravenous antibiotics
3 Major debridement, artery repair
Fever of unknown origin 1 Prolongation of hospital stay
Implant-related complications
Ruptured aneurysm 2 Endovascular repair with survival and no permanent morbidity
3 Open surgical repair or fatal outcome
Endograft migration ( 10 mm relative to
anatomical landmarks or any migration
leading to symptoms or requiring therapy)
1 No evidence of endoleak, graft obstruction, or aneurysm expansion
2 Secondary endovascular treatment
3 Explantation necessitated, AAA rupture, death
Endograft infection 2 Apparently resolved or controlled with antibiotics
3 Endograft removal with extraanatomic or in situ repair
Device erosion through aortic or iliac wall 2 Successful endovascular repair
3 Surgical intervention or fatal outcome
Intraoperative endograft limb obstruction 1 Resolved at primary procedure and not associated with thrombosis
2 Limited retroperitoneal repair or thrombectomy
3 Bypass or conversion
Postoperative endograft limb obstruction 2 Resolved with endovascular repair, minor tissue loss, including toe or ray
amputation
3 Lytic therapy or open operative repair, major amputation
Buttock/leg claudication/ischemia 1 Transient
2 Persistent but not disabling (controlled with exercise or pharmacotherapy)
3 Sufficiently disabling to necessitate intervention
(continued on next page)
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ing precise gradations of severity. Nevertheless, complica-
tions should be assigned a severity score so that degrees of
morbidity can be assessed and compared. The following
scoring system has been modified from Rutherford et al.55
Mild (1) indicates that the complication has occurred but
resolved spontaneously or with nominal intervention, did
not prolong hospital stay, and did not cause permanent
impairment. Moderate (2) indicates the need for significant
intervention, prolongation of hospitalization more than 24
hours, and at most, minor permanent disability that does
not preclude normal daily activity. A severe complication (3)
necessitates major surgical or medical intervention, may be
associated with prolonged convalescence, is usually accom-
panied by prolonged or permanent disability, and may
result in death.56
Complications are presented in Table VII. Column 1
lists individual complications with specific definitions as
needed and details for inclusion. Column 2 provides addi-
tional specifications for severity grading beyond the general
criteria described previously. All complications should be
classified as procedure-related or device-related, and ana-
tomic site and presumed etiology should be reported where
appropriate. All complications graded as moderate (2) or
severe (3) are considered major complications, and those
graded as mild (1) can be considered minor complications.
INVESTIGATOR DISCLOSURE AND CONFLICT
OF INTEREST
Most publications relating to endovascular aneurysm
repair will be based on information acquired during indus-
try-sponsored clinical trials. In varying degrees, most au-
thors and their institutions will have direct or indirect
monetary relationships with these sponsors or their com-
petitors. Although other factors have significant impact on
author bias, financial issues are considered the most rele-
vant. Disclosure does not in itself resolve the problem;
however, it places this information before readers who can
draw their own conclusions. Disclosure also may enhance
authors’ efforts to recognize and avoid bias in their presen-
tations.
The International Committee of Editors of Biomedical
Journals has established guidelines for disclosure of con-
flicts of interest.57 On the basis of these guidelines, the
Journal of Vascular Surgery has published its formal re-
quirements for all authors of a submitted article.58,59 These
requirements include disclosure of: (1) university, institu-
tional, and corporate relationships; (2) a list of sources of
funding received for the reported investigation and other
investigations supported within 3 years of manuscript ac-
ceptance by organizations that may have a competitive or
Table VII. Continued.
Complication Grading
Systemic complications
Cardiac 1 Little or no hemodynamic consequence
2 Symptomatic necessitating intravenous medication, percutaneous transluminal
coronary angioplasty/stent therapy
3 Severe hemodynamic dysfunction necessitating resuscitation, cardiac arrest, or
fatal outcome
Pulmonary 1 Prompt recovery with medical treatment
2 Prolonged hospitalization or intravenous antibiotics
3 Prolonged intubation, tracheostomy, deterioration in pulmonary function, O2
dependence, or fatal outcome
Renal insufficiency 1 No dialysis
2 Temporary dialysis, prolonged hospitalization, permanently reduced renal
function
3 Permanent dialysis, transplant, or fatal outcome
Cerebrovascular 1 Temporary deficit with recovery within 24 hours
2 Delayed recovery, infarct on CT or magnetic resonance, permanent deficit with
mild impairment
3 Severe impairment or fatal outcome
Deep venous thrombosis 2 Anticoagulation therapy, inferior vena cava filter
3 Surgical or lytic therapy
Pulmonary embolism 2 Anticoagulation therapy, inferior vena cava filter
3 Hemodynamic instability, endovascular or surgical therapy, or fatal outcome
Coagulopathy 2 Transfusion therapy
3 Surgical intervention or fatal outcome
Bowel ischemia 1 Recovered without intervention
2 Recovered with intravenous antibiotics or total parenteral nutrition
3 Bowel resection, or fatal outcome
Spinal cord ischemia 1 Resolution within 24 hours
2 Resolution within 1 month or minor permanent deficit, able to walk without
support
3 Major permanent deficit
Erectile dysfunction 1 Spontaneous recovery to preoperative status within 6 months
2 Functional with medical or injection therapy
3 No return of function or implant necessitated
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antagonistic interest; and (3) potential financial conflicts,
including consulting arrangements, board membership or
employment, royalties, stock holdings, or option agree-
ments with the company relating to the publication or its
competitors. In addition to the admission of financial rela-
tionships, authors should describe within the Methods
section of a manuscript the respective roles of study spon-
sors and investigators in: (1) study design; (2) conduct of
the study; (3) data collection; (4) data analysis; (5) data
interpretation; (6) writing of the manuscript; and (7) the
decision regarding where and when to submit the report for
publication. In this regard, clear relationships should be
established between the investigator and company before
the initiation of the investigation to avoid the potential of
manuscript rejection by the Journal of Vascular Surgery or
by other scholarly publications. As a final note, disclosure
also offers an opportunity to reveal any further personal,
academic, or other conflict that might introduce bias.
These guidelines should be followed by all listed authors
with a standard form provided by the publisher or as a
formal statement in the body of the text or a footnote.
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